Brief: Compass Therapeutics Reports Q4 Loss Per Share Of $0.15
21/03/2022 12:21
March 21 (Reuters) - Compass Therapeutics Inc. CMPX.O :
* COMPASS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2021
FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* Q4 LOSS PER SHARE $0.15
* ANTICIPATED CASH RUNWAY INTO SECOND HALF OF 2024
Source text for Eikon: ID:nGNX3gPHCy
Further company coverage: CMPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback